SECTOR
Dr. Reddy’s launches Bosutinib Tablets 400mg in US
Jun-13-2026

Dr. Reddy’s Laboratories has launched Bosutinib Tablets 400mg, a generic equivalent of Bosulif, first-to-market in the United States (US), expanding its oncology portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. Dr. Reddy’s has collaborated with MSN Laboratories (MSN), a leading pharmaceutical company in India, on this product. 

Dr. Reddy’s holds the exclusive marketing rights for the product in the United States. MSN is responsible for the development and manufacturing of the product. Bosutinib Tablets (400mg) was a first-to-file product and is eligible for 180-days of generic drug exclusivity for this strength, in the U.S.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas. 


  RELATED NEWS >>